Is Asarfi Hospital overvalued or undervalued?

As of 28 October 2025, the valuation grade for Asarfi Hospital has moved from very attractive to attractive. The company appears to be fairly valued based on its current metrics. Key ratios include a PE ratio of 29.52, an EV to EBITDA of 15.57, and a PEG ratio of 0.18, which suggests strong growth potential relative to its price.
When compared to peers, Asarfi Hospital's valuation stands out; for instance, Max Healthcare is categorized as very expensive with a PE of 95.25, while Apollo Hospitals is rated fair with a PE of 72.19. Despite being attractive, Asarfi Hospital's ratios indicate it is not undervalued, especially given the significant outperformance against the Sensex, with a 1-year return of 165.73% compared to the Sensex's 5.78%.